TL;DR: Aetna, a CVS Health company, modified CPB 0918 governing edaravone injection (Radicava and generic) coverage for ALS, with an effective date of December 10, 2025. Billing teams using HCPCS J1301 and CPT 96365 need to verify prior authorization is in place and that clinical documentation satisfies all updated medical necessity criteria before submitting claims.
This Aetna edaravone injection coverage policy update tightens what documentation you need to get J1301 paid. The policy covers both branded Radicava and its generic formulation under commercial plans — and it requires precertification for every claim. If your neurology or infusion practice bills edaravone injection billing for ALS patients, this change is worth a close read before December 10, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Edaravone Injection — CPB 0918 |
| Policy Code | CPB 0918 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High |
| Specialties Affected | Neurology, Neuromuscular Medicine, ALS Specialty Clinics, Infusion Centers |
| Key Action | Confirm ALSFRS-R scores and ventilatory status are documented before submitting J1301 claims on or after December 10, 2025 |
Aetna Edaravone Injection Coverage Criteria and Medical Necessity Requirements 2025
CPB 0918 Aetna covers edaravone injection under commercial plans only. Medicare criteria live elsewhere — check Aetna's Medicare Part B step therapy page if that's your patient population.
Precertification is not optional. Every claim for J1301 (injection, edaravone, 1 mg) requires prior authorization before treatment starts. Call (866) 752-7021 or fax (888) 267-3277 to initiate. If you're routing through a Statement of Medical Necessity form, those are on Aetna's Specialty Pharmacy Precertification page.
Initial Approval: Three Criteria, All Required
Aetna considers edaravone medically necessary for ALS only when the member meets all three of the following:
| # | Covered Indication |
|---|---|
| 1 | Confirmed diagnosis of definite or probable ALS. Supporting documentation must include medical history and diagnostic testing — nerve conduction studies, imaging, or lab values. One of these alone probably won't cut it. Build a complete record. |
| 2 | ALSFRS-R scores of at least 2 on all 12 domains. The revised ALS Functional Rating Scale has 12 domains. The member must score at least 2 on every single one — not an average of 2, not most domains. All 12. This is the criterion most likely to trip up your documentation. Get the full scored scale in the chart, not just a summary note. |
| 3 | No continuous ventilatory support during day and night. Noninvasive or invasive ventilation used around the clock disqualifies the member at initial authorization. Intermittent use isn't explicitly excluded here, but document the ventilatory status precisely. |
Continuation of Therapy: Different Bar, Still Strict
Continuation criteria are distinct from initial approval. For ongoing coverage, the member must meet all of these:
| # | Covered Indication |
|---|---|
| 1 | Definite or probable ALS diagnosis remains documented. |
| 2 | Clinical benefit from edaravone is demonstrated. "Benefit" is not defined by the policy — which means your documentation needs to show it explicitly. Functional stability counts. Slowed decline likely counts. Get your neurologist to state it plainly in the chart note. |
| 3 | Invasive ventilation is not required. Note the language shift here: continuation drops the "noninvasive or invasive during day and night" framing and simply says invasive ventilation disqualifies. A patient using nighttime BiPAP (noninvasive) may still qualify for continuation even if they're more limited than at initial approval. If you're unsure how this applies to a specific patient's ventilatory status, loop in your compliance officer before reauthorization. |
Prescriber Requirement
The prescribing physician must be a neurologist, neuromuscular specialist, or physician specializing in ALS treatment. A primary care physician writing the order alone won't satisfy this requirement. Co-management arrangements are acceptable — "in consultation with" a qualifying specialist covers it.
Site of Care
Aetna's Site of Care Utilization Management Policy applies to edaravone infusion. This is the same site-of-care management framework Aetna applies to other specialty drug infusions. It means the payer may redirect patients from hospital outpatient settings to lower-cost infusion sites. Check Aetna's drug infusion site-of-care policy before you schedule infusions — this directly affects your reimbursement and your claim denial risk.
Aetna Edaravone Injection Exclusions and Non-Covered Indications
The coverage policy is explicit: all indications other than ALS are considered experimental, investigational, or unproven.
This matters because the ICD-10 code list attached to CPB 0918 is long — 183 codes spanning Alzheimer's disease, multiple sclerosis, Parkinson's disease, cerebral infarction, epilepsy, acute pancreatitis, and more. Those codes appear in the policy for research context, not for coverage. Aetna will not pay J1301 for those diagnoses under this policy.
Billing J1301 with G12.21 (amyotrophic lateral sclerosis) is the only covered path. If you see a claim go out with any other primary diagnosis, that's a denial waiting to happen.
Also worth flagging: this policy addresses only edaravone injection. Oral edaravone (Radicava ORS) runs through a separate pharmacy CPB. Sodium phenylbutyrate/taurursodiol (Relyvrio) runs through the pharmacy benefit plan entirely. Don't mix these up in your precertification workflow — wrong benefit path means delayed authorization and likely a claim denial.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Definite or probable ALS — initial therapy (ALSFRS-R ≥2 all domains, no continuous ventilation) | Covered | J1301, CPT 96365, G12.21 | Precertification required; prescriber must be neurologist or neuromuscular specialist |
| Definite or probable ALS — continuation therapy (clinical benefit shown, no invasive ventilation) | Covered | J1301, CPT 96365, G12.21 | Reauthorization required; document clinical benefit explicitly |
| ALS with continuous ventilatory support (day and night) — initial therapy | Not Covered | — | Both noninvasive and invasive ventilation disqualify at initial approval |
| ALS requiring invasive ventilation — continuation therapy | Not Covered | — | Invasive ventilation disqualifies at continuation; noninvasive may still qualify |
| All other indications (Alzheimer's, MS, Parkinson's, stroke, etc.) | Experimental / Not Covered | — | Policy explicitly excludes all non-ALS indications |
| Oral edaravone (Radicava ORS) | Out of Scope | — | Covered under separate pharmacy CPB |
| Sodium phenylbutyrate/taurursodiol (Relyvrio) | Out of Scope | — | Covered under pharmacy benefit plan |
Aetna Edaravone Injection Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Verify precertification is active before December 10, 2025 for all current edaravone patients. Don't wait for renewals to catch this. Pull your active J1301 authorizations now and confirm they're current under CPB 0918. Any gap in authorization means a gap in payment. |
| 2 | Audit your ALSFRS-R documentation for every patient on edaravone. The 12-domain, all-at-2 threshold is the hardest criterion to document consistently. Review your chart note templates with your neurology team. If the scored rating scale isn't in the record, get it there before the next authorization submission. |
| 3 | Document ventilatory status explicitly at each visit. "No continuous ventilatory support" needs to be stated in the clinical note — not implied, not inferred from other chart elements. Train your clinical staff to include this language at every encounter for ALS patients on edaravone. |
| 4 | Confirm the correct prescriber is on record. If a patient's edaravone was prescribed by a PCP without a documented consulting neurologist, get the co-management documentation in place now. Authorizations tied to a non-qualifying prescriber will deny. |
| 5 | Check the site-of-care designation before scheduling infusions. Aetna's infusion site-of-care policy is a live policy that can redirect patients away from your facility. Confirm the authorized site before booking infusion appointments. A site mismatch is a billing guidelines violation that generates denials regardless of clinical eligibility. |
| 6 | Separate your edaravone injection authorization workflow from oral edaravone and Relyvrio. These are different benefit pathways with different forms, different phones, and different coverage rules. A single mixed workflow produces authorization errors across all three products. Keep them separate. |
| 7 | Use G12.21 as the primary diagnosis code. This is the correct ICD-10-CM code for amyotrophic lateral sclerosis. The 183-code list in CPB 0918 is not a covered indication list — it's background clinical context. Billing with any other primary diagnosis will result in a claim denial. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Edaravone Injection Under CPB 0918
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J1301 | HCPCS | Injection, edaravone, 1 mg |
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
Key ICD-10-CM Diagnosis Codes
The table below lists the primary covered diagnosis and the full range of codes present in CPB 0918. Only G12.21 is a covered indication. All others appear in the policy for clinical background context and are explicitly excluded from coverage.
| Code | Description | Coverage Status |
|---|---|---|
| G12.21 | Amyotrophic lateral sclerosis | Covered (when all criteria met) |
| E06.3 | Autoimmune thyroiditis | Not covered |
| F06.31 | Mood disorder due to known physiological condition with depressive features | Not covered |
| G20.A1–G21.C | Parkinson's disease (range) | Not covered |
| G30.0–G30.9 | Alzheimer's disease (range) | Not covered |
| G35 | Multiple sclerosis | Not covered |
| G40.001–G40.919 | Epilepsy and recurrent seizures (range) | Not covered |
| G93.40 | Encephalopathy, unspecified | Not covered |
| H31.8 | Other specified disorders of choroid (choroidal neovascularization) | Not covered |
| I25.5 | Ischemic cardiomyopathy | Not covered |
| I60.0–I60.9 | Nontraumatic subarachnoid hemorrhage (range) | Not covered |
| I61.0–I61.9 | Nontraumatic intracerebral hemorrhage (range) | Not covered |
| I63.0–I63.9 | Cerebral infarction (range) | Not covered |
| I69.398 | Other sequelae of cerebral infarction | Not covered |
| J45.20–J45.998 | Asthma (range) | Not covered |
| K85.0–K85.29 | Acute pancreatitis (range) | Not covered |
The full ICD-10-CM code list in CPB 0918 contains 183 codes. The table above represents the complete set provided in the policy data. All non-ALS codes are experimental or not covered under this policy.
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.